特立妥單抗，Teclistamab，CAS:2119595-80-9， AntibodySystem Laboratories

貨號(hào)：DHF92402

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75181.html

別名：Bispecific, BCMA, JNJ-64007957, JNJ-7957, Ab-957, CAS: 2119595-80-9

簡(jiǎn)介：Teclistamab是一種人源化的BCMA和CD3雙特異性抗體，可識(shí)別靶細(xì)胞上的BCMA和T細(xì)胞上的CD3，誘導(dǎo)T細(xì)胞介導(dǎo)的細(xì)胞毒性，導(dǎo)致T細(xì)胞的活化和隨后的靶細(xì)胞裂解。Teclistamab可用于多發(fā)性骨髓瘤等相關(guān)疾病研究。

貨號(hào)：DHF92402

產(chǎn)品品牌：Antibodysystem

通用名：Teclistamab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：Bispecific, BCMA, JNJ-64007957, JNJ-7957, Ab-957

靶點(diǎn);物種：Human CD269/TNFRSF17/BCMA & CD3E

種類：Chimeric/Homo sapiens

受體鑒定：IgG4-lambda

CAS: 2119595-80-9

存儲(chǔ)條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

Teclistamab in Relapsed or Refractory Multiple Myeloma. PMID: 36322859
Teclistamab, a B-cell maturation antigen?×?CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. PMID: 34388396
Teclistamab: First Approval. PMID: 36352205
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. PMID: 32956453
Teclistamab. PMID: 36795903
Teclistamab-cqyv. PMID: 36645056
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. PMID: 35749004
Teclistamab-cqyv (Tecvayli) for multiple myeloma. PMID: 36384770
Effects of teclistamab and talquetamab on soluble BCMA levels in?patients with relapsed/refractory multiple myeloma. PMID: 36006441
Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply. PMID: 36322861
MajesTEC results with teclistamab in?RRMM. PMID: 34453130
Antibodies to watch in 2023. PMID: 36472472
Teclistamab impairs detection of BCMA CAR-T cells. PMID: 37026812
[Teclistamab for the treatment of multiple myeloma]. PMID: 36478107
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. PMID: 37114426
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma. PMID: 37132225
Antibodies and bispecifics for multiple myeloma: effective effector therapy. PMID: 36485135
The emerging therapeutic landscape of relapsed/refractory multiple myeloma. PMID: 36462062
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. PMID: 37009408
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. PMID: 35913648
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. PMID: 36961654
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. PMID: 36967244
Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. PMID: 36875718
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. PMID: 33227097
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. PMID: 36991547
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. PMID: 36775940
Anti-BCMA novel therapies for multiple myeloma. PMID: 37065871
A BCMA-Targeted Bispecific Antibody Is Active in Multiple Myeloma. PMID: 34417227
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. PMID: 36980705
Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End? PMID: 37111346

?